HeartSciences Inc. Warrant - HSCSW STOCK NEWS

HeartSciences, an AI-powered medical technology company, has been granted a fundamental patent by the European Patent Office for assessing diastolic function of the heart using AI-ECG. Diastolic dysfunction is important for early detection of heart disease, preceding symptoms. The patent covers the use of AI-ECG for any echo measure of diastolic function, making it a valuable tool for heart screening in clinical settings. This patent reinforces HeartSciences' position in AI-ECG technology and is expected to drive significant growth in the ECG market.

HeartSciences, an AI-powered medical technology company, announced CEO Andrew Simpson's presentation at the LD Micro Invitational XIV Conference. The focus is on transforming ECGs/EKGs for early heart disease detection.

HeartSciences (NASDAQ: HSCS) presented a study showcasing the effectiveness of MyoVista wavECG in screening preoperative patients for LVDD at the 18th World Congress of Anesthesiologists. The study demonstrated 100% sensitivity in detecting LVDD, potentially reducing unnecessary referrals to echocardiography. MyoVista wavECG shows promise in transforming cardiovascular medicine and is set to be commercially available soon.

HeartSciences, a medical technology company, reported Q3 FY2024 financial results showing a strengthened financial position, strategic shifts, and business highlights. Key accomplishments include acquiring AI-ECG algorithms from Mount Sinai, FDA pathway changes, and enhanced team recruitment. The company aims to lead the AI-ECG market with improved financials, extended cash runway, and clinical advancements.

HeartSciences (NASDAQ: HSCS) announces a study showing MyoVista AI-ECG model outperforms NT-proBNP and ARIC HF score in Stage B Heart Failure screening among type 2 diabetes patients. The study highlights the potential of AI-ECG technology to enhance heart disease detection and screening processes.

HeartSciences, an AI-powered medical technology company, has received a patent grant from the Canadian Intellectual Property Office for its AI-ECG technology. The company aims to revolutionize heart disease detection, reduce treatment costs, and capitalize on the growing ECG market, with a projected value of $25 billion by 2032.

HeartSciences appoints Dr. Partho P. Sengupta, a renowned cardiologist, to its Scientific Advisory Board. Dr. Sengupta brings vast experience and expertise in AI-ECG technology, enhancing HeartSciences' position in the field.

HeartSciences appoints Dr. Jordan B. Strom to its Scientific Advisory Board, enhancing expertise in AI-based medical devices and preparing for FDA submission of MyoVista device and cloud platform.

HeartSciences (HSCS) appoints Dr. Benjamin Glicksberg, an elite data scientist and lead investigator of AI algorithms licensed by the company, to its Scientific Advisory Board. The appointment follows the recent closing of agreements with Mount Sinai, covering an industry-leading portfolio of AI-based ECG/EKG algorithms, technologies, and patent rights for the screening and diagnosis of cardiovascular disease. The company aims to achieve significant milestones, including launching a hardware-agnostic cloud platform to deliver the AI-ECG algorithms licensed from Mount Sinai and obtaining FDA clearance for its MyoVista wavECG device. Dr. Glicksberg's expertise in machine learning, digital health, and bioinformatics is expected to contribute to expanding the clinical diagnostic capabilities of the ECG/EKG, transforming the early detection of heart disease.